Context Therapeutics (CNTX) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Quoin Pharmaceuticals (QNRX) has outperformed Context Therapeutics (CNTX) over the past year, losing 82.1% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | QNRX |
|---|---|---|
| Share price | $0.16 | $3.28 |
| Market cap | $14.70M | $15.76M |
| 1-day change | -5.10% | -2.35% |
| YTD return | -89.12% | -77.27% |
| 1-year return | -85.32% | -82.07% |
| 5-year return | -96.86% | -99.99% |
| P/E ratio (TTM) | — | 7.45 |
| EPS (TTM) | $-0.46 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-36.12M | $-15.80M |
| 52-week high | $3.62 | $23.50 |
| 52-week low | $0.153 | $3.18 |
| Distance from 52-week high | -95.58% | -86.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +2418.75% | +565.55% |
| Average volume | 1.42M | 541.26K |
| Shares outstanding | 91.88M | 4.80M |
| Employees | 15 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
CNTX vs QNRX FAQ
Which is bigger, Context Therapeutics or Quoin Pharmaceuticals?
Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $14.70M for Context Therapeutics (CNTX).
Which stock has performed better over the past year, CNTX or QNRX?
QNRX returned -82.07% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.